950769-62-7

Basic information

• Product Name: N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea hydrochloride
• Synonyms: N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea hydrochloride
• CAS NO: 950769-62-7
• Molecular Formula: C29H32N6O4S.HCl
• Molecular Weight: 597.12812
• Mol File: 950769-62-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea hydrochloride(950769-62-7)
• EPA Substance Registry System: N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea hydrochloride(950769-62-7)

Safety Data

• Hazardous Substances Data: 950769-62-7(Hazardous Substances Data)

Usage

General Description

N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea hydrochloride is a chemical compound that is a potent and selective inhibitor of the protein kinase known as fibroblast growth factor receptor (FGFR). FGFR plays a critical role in regulating cell growth, survival, and differentiation, and is often overactive in various types of cancer. Therefore, inhibitors of this kinase have shown potential as anti-cancer agents. N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea hydrochloride is a hydrochloride salt, which means it is more water-soluble and stable than the free base form. The specific chemical structure of this compound makes it a promising candidate for further development as a targeted therapy for cancers driven by FGFR activation.

Upstream product

• 950769-58-1 quizartinib 
• 55809-36-4 3-amino-5-tert-butylisoxazole 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 
• 26278-79-5 2-amino-6-hydroxybenzothiazole 
• 914224-34-3 2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazol-7-ol 
• 950769-60-5 4-(2-((2-(4-nitrophenyl)benzo[d]imidazo[2,1-b]thiazol-7-yl)oxy)ethyl)morpholine 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES

Provided herein are process for the preparation of N-(5-ferf-butyl-isoxazol-3-yl)- N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-fe][l,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof. N-(5-tert- Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-and][l,3]benzo- thiazol-2-yl]phenyl}urea is useful for treating, preventing, and/or managing diseases or conditions, including but not limited to, proliferative diseases, FLT-3 mediated diseases, and cancers. N-(5-ferf-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl- ethoxy)imidazo[2,l-and][l,3]benzothiazol-2-yl]phenyl}urea is represented by the structure:

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2- morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharma